Responses
Regular and young investigator award abstracts
Immunotherapy toxicities
654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors
Compose a Response to This Article
Other responses
No responses have been published for this article.
